Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks
Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (INCY) and Biogen (BIIB) as top stock picks, focusing on healthcare over AI. Incyte's stock is up 22% this year, with strong earnings and a growing drug pipeline. The company reported 38% revenue growth and raised its 2026 sales guidance. Risks include Jakafi's patent expiration and competition for Opzelura.
How this was made
The 30-second read
Why it matters
The guidance upgrade may attract momentum traders and boost Incyte's valuation, while competitors watch for pipeline risks.
Market read
Incyte's upgraded outlook provides a fresh catalyst for biotech investors, potentially influencing sector sentiment.
What to watch
Potential competitive pressure from AbbVie's Rinvoq in vitiligo could curb Opzelura growth.
Background
Josh Brown recommends Incyte as a top healthcare pick, citing its earnings momentum, guidance raise, and upcoming data readouts.
Ticker impact
Incyte raised its FY2026 sales guidance by about 7% and lifted Opzelura outlook ~40%, adding 10 H2 clinical readouts as catalysts.
Potential upside of 5‑10% over the next few weeks if guidance holds.
Guidance beats prior expectations and adds multiple data readouts, reducing downside risk.
Market effects
Biotech sector may see renewed investor interest as Incyte's pipeline diversification reduces reliance on a single product.
U.S. biotech equities could benefit, with limited immediate effect on broader markets.
Guidance lift highlights ongoing demand for oncology and dermatology therapies worldwide.
Counterpoint
If Jakafi loses exclusivity sooner than expected, the guidance may be overly optimistic.
Key entities
- CompanyIncyte Corporation
Biotech firm developing Jakafi and Opzelura, raised FY2026 guidance.
- PersonJosh Brown
CEO of Ritholtz Wealth Management, provided the stock recommendation.
